Eurand N.V. (EURX) announced the commercial availability of Zenpep (pancrelipase) Delayed-Release Capsules, a pancreatic enzyme product or PEP indicated for the treatment of exocrine pancreatic insufficiency or EPI due to cystic fibrosis or CF or other conditions. The U.S. Food and Drug Administration approved Zenpep on August 27, 2009.
Eurand has also completed the hiring, training and deployment of its sales organization to promote Zenpep, including a specialty CF sales force composed of 16 Eurand sales people targeting the 120 accredited cystic fibrosis centers, satellites and other specialists who treat CF.
In addition, the Company has contracted with Innovex, a Quintiles company, to promote Zenpep to PEP prescribers who commonly treat patients with EPI associated with other conditions such as chronic pancreatitis, pancreatic cancer and gastric surgery. These 49 Innovex sales professionals will call on key gastroenterologists, internal medicine specialists, family-practice physicians and oncologists.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.